Wednesday, August 17, 2016 8:44:03 AM
"Several observations: ARTH cannot fully publish data and then get an article in a peer-reviewed publication. Strategic partners look at peer-reviewed publications as being the litmus test of credibility.
The ARTH advisory group is not going to risk their scientific credibility by hyping the results of this initial trial so I place great emphasis on what they have to say.
Anyone who doesn't think a 41% reduction in bleeding is significant is a moron. ANYTIME you can reduce bleeding time, you do so. Period. Ask any surgeon.
Finally, any company in this space that shows even modest results is eventually purchased. I have no doubt that ARTH will find a strategic partner or get purchased and at multiples significantly higher than the stock price today."
Elevator Summary of ARCH http://www.archtherapeutics.blogspot.com/
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM